Ratain Curriculum Vitae – Revised 12/19/2016
`
`Date of Birth:
`Place of Birth:
`Marital Status:
`
`Education
`
`1976
`
`1980
`
`MARK J. RATAIN, M.D.
`
`November 23, 1954
`Washington, D.C.
`Married
`
`Harvard University, A.B. (biochemical sciences, magna cum laude)
`
`Yale University School of Medicine, M.D. (thesis -"Elicitation of the late nasal and
`cutaneous response: the possible role of eosinophils and basophils")
`
`Professional Positions
`
`1972-1977
`
`Computer programmer/systems analyst - part-time. System Sciences, Inc., Bethesda,
`MD
`
`1980-1981
`
`Intern, Osler Medical Service, Johns Hopkins Hospital, Baltimore, MD
`
`1981-1983
`
`Resident, Osler Medical Service, Johns Hopkins Hospital, Baltimore, MD
`
`1983-1986
`
`Fellow, Section of Hematology/Oncology, Department of Medicine, The University of
`Chicago, Chicago, IL
`
`1986-1988
`
`Associate Attending Member, Department of Medicine, Division of Hematology/Oncology,
`Michael Reese Hospital and Medical Center, Chicago, IL
`
`1986-1987
`
`Instructor, Department of Medicine, Section of Hematology/Oncology, and Committee on
`Clinical Pharmacology, The University of Chicago, Chicago, IL
`
`1987-1991
`
`Assistant Professor, Department of Medicine, Section of Hematology/Oncology, and
`Committee on Clinical Pharmacology, The University of Chicago, Chicago, IL
`
`1988-1989
`
`Attending Member, Department of Medicine, Division of Hematology/Oncology, Michael
`Reese Hospital and Medical Center, Chicago, IL
`
`1988-1992
`
`Director of Clinical Pharmacology, Section of Hematology/Oncology, The University of
`Chicago, Chicago, IL
`
`1991-1995
`
`Director, Developmental Therapeutics Program, Cancer Research Center, The University
`of Chicago, Chicago, IL
`
`1991-1995
`
`1992-2010
`
`1995-2002
`
`Associate Professor, Department of Medicine, Section of Hematology/Oncology,
`Committee on Clinical Pharmacology, and Cancer Research Center, The University of
`Chicago, Chicago, IL
`
`Chairman, Committee on Clinical Pharmacology and Pharmacogenomics*, The University
`of Chicago, Chicago, IL
`
`Professor, Department of Medicine, Section of Hematology/Oncology, Committee on
`Clinical Pharmacology and Pharmacogenomics*, and Cancer Research Center, The
`University of Chicago, Chicago, IL
`
`1
`
`Amerigen Exhibit 1092
`Amerigen v. Janssen IPR2016-00286
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`1995-2000
`
`Co-Director, Clinical and Experimental Therapeutics Program, Cancer Research Center,
`The University of Chicago, Chicago, IL
`
`2002-
`
`1999-
`
`2010-
`
`Leon O. Jacobson Professor, Department of Medicine, Section of
`Hematology/Oncology, Committee on Clinical Pharmacology and
`Pharmacogenomics*, and Comprehensive Cancer Centert, The University of
`Chicago, Chicago, IL
`
`Associate Director for Clinical Sciences, Comprehensive Cancer Center
`University of Chicago, Chicago, IL
`
`t
`
`, The
`
`Director, Center for Personalized Therapeutics, The University of Chicago,
`Chicago, IL
`
`2010-
`
`Chief Hospital Pharmacologist, The University of Chicago Medicine&, Chicago, IL
`
`*previously Committee on Clinical Pharmacology
`t
`previously Cancer Research Center
`&previously University of Chicago Medical Center
`
`2
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`Research Review and Related Federal Service
`
`National Institutes of Health
`Ad Hoc Reviewer, Experimental Therapeutics Study Section, Division of Research Grants 1986
`Special Review Committee, National Cancer Institute 1991
`Consultant Reviewer, Department of Veteran Affairs 1993
`Ad Hoc Reviewer, National Cancer Institute 1993
`Special Study Section (Small Business Innovative Research Program), Division of Research
`Grants 1994
`Ad Hoc Reviewer, National Center for Research Resources 1997
`Reviewer, Intramural Review Office, Pediatric Oncology Branch, National Cancer Institute 1998
`Clinical Oncology Special Emphasis Panel, Oncological Science Initial Review Group, Center for
`Scientific Review 1999-2000
`Clinical Advisory Working Group, National Institute of General Medical Sciences 1999
`Ad Hoc Reviewer, Drug Development Group, National Cancer Institute 2000, 2001
`Data and Safety Monitoring Board (T-Cell Depleted Auto Stem Cell Transplant Trial for Systemic
`Sclerosis), National Institute of Arthritis and Musculoskeletal Diseases 2002-2005
`Clinical Trials Working Group, National Cancer Advisory Board, National Cancer Institute 2004-
`2005
`Investigational Drug Steering Committee, National Cancer Institute 2005-2016 (Co-Chair, Steering
`Committee, 2005-2008; Co-Chair, Clinical Trials Design Task Force, 2012-2016)
`National Institute of General Medical Sciences Special Emphasis Panel 2006
`Subcommittee J - Population and Patient-Oriented Training, National Cancer Institute Initial
`Review Group (Ad Hoc Reviewer 2006; Member 2006-2009)
`Reviewer, NIH Director’s New Innovator Awards 2008
`Reviewer, Center for Scientific Review 2010
`National Institute of General Medical Sciences Special Emphasis Panel 2013, 2014
`
`Dutch Cancer Society
`Ad Hoc Reviewer 1994, 1999
`
`The Cancer Society of New Zealand
`Ad Hoc Reviewer 1994
`
`Joint Infrastructure Fund, Wellcome Trust
`Ad Hoc Reviewer 1998, 2000
`
`Institut National du Cancer
`Ad Hoc Reviewer 2010
`
`Christian Doppler Research Association
`Ad Hoc Reviewer 2011
`
`Pennsylvania Department of Health
`Ad Hoc Reviewer 2012-2014, 2016
`
`Florida Department of Health
`Ad Hoc Reviewer 2015-2016
`
`3
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`National and International Organizations
`
`Cancer and Leukemia Group B
`Chemotherapy Committee 1988-1990
`Breast Committee 1989-1998
`Ad Hoc Committee on Relations with Pharmaceutical Companies 1989-1990
`Pharmacology and Experimental Therapeutics Committee 1990-2011 (Chair, 1994-2011)
`Ad Hoc Nominating Committee 1989-1990
`Industrial Relations Committee 1992-1993
`Executive Committee 1993-1996
`Board of Directors 1993-2011
`Chair, Ad Hoc Committee on Conflict of Interest 1994-1996
`Chair, Conflict of Interest Committee 1996-1998
`
`American Federation for Clinical Research
`Medical School Representative 1988-1989
`
`American Society for Clinical Pharmacology and Therapeutics
`Hematologic and Neoplastic Diseases Section 1988-2007 (Vice Chair, 1988-1992; Chair, 1992-
`1995)
`Government Affairs Committee 1990-2002 (Vice Chair, 1997-2002)
`Long Range Planning Committee 1990-1993
`Committee on Coordination of Scientific Sections 1992-1995, 1998-2001 (Chair, 1998-2001)
`Scientific Program Committee 1993-1994, 1996-1998, 2001-2004 (Vice Chair 2001-2002, Chair
`2002-2003, Immediate Past Chair 2003-2004)
`Nominating Committee 1995-1996
`Board of Directors 1997-2001
`Executive Committee 1998-2001
`Communications and Public Relations Committee 1998-2001
`Committee on Substance Abuse 1998-2001
`Membership Committee 2000-2003
`Molecular Pharmacology and Pharmacogenetics Section 2001-
`Pharmacokinetics and Drug Metabolism Section 2001-2007
`Oncology Section 2007-
`Pharmacometrics and Pharmacokinetics 2007-
`
`International Workshops on Pharmacodynamics of Anticancer Agents
`First International Workshop on Pharmacodynamics of Anticancer Agents (Fontana, WI), Co-
`Organizer 1989
`Second International Workshop on Pharmacodynamics of Anticancer Agents (Eze, France), Co-
`Organizer 1992
`Third International Workshop on Pharmacodynamics of Anticancer Agents (Irvington, VA), Co-
`Organizer 1995
`Fourth International Workshop on Pharmacodynamics of Anticancer Agents (Dunkeld, Scotland),
`Co-Organizer 1998
`Fifth International Workshop on Pharmacodynamics of Anticancer Agents (Sea Island, GA), Co-
`Organizer 2001
`Sixth International Workshop on Pharmacodynamics of Anticancer Agents (Venice, Italy), Co-
`Organizer 2004
`Seventh International Workshop on Pharmacodynamics of Anticancer Agents (Guanacaste,
`Costa Rica), Co-Organizer 2007
`Eighth International Workshop on Pharmacodynamics of Anticancer Agents (Hakone, Japan), Co-
`Organizer 2010
`Ninth International Workshop on Pharmacodynamics of Anticancer Agents (Hexham, England),
`Co-Organizer 2013
`Tenth International Workshop on Pharmacodynamics of Anticancer Agents (Skamania, WA), Co-
`Organizer 2016
`
`4
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`American Society of Clinical Oncology
`Committee for Patient Advocacy 1990-1992
`Audit and Finance Committee 1990-1994 (Chair, 1990-1994)
`Secretary-Treasurer 1994-1997
`Board of Directors 1994-1997
`Executive Committee 1994-1997
`Strategic Planning Committee 1994-1998
`Program Committee 1995-1997, 1998-2000 (Subchair for Clinical Pharmacology, 1995-1996;
`Board Liaison, 1995-1996)
`Industry/Exhibits Committee 1995-1997 (Board Liaison, 1995-1997)
`Ad Hoc Committee to Develop ASCO OnLine 1995
`Clinical Methods Workshop Program Committee 1995-1997
`OnLine Committee 1995-2000
`Subcommittee on Phase I Clinical Trials, Public Issues Committee 1996 (Chair, 1996)
`Publications Committee 1997-2000 (OnLine Committee Liaison 1997-2000)
`Continuing Medical Education Committee 1997-2000 (Chair, 1997-1999; Immediate Past Chair,
`1999-2000)
`Cancer Education Committee 2000-2003 (Track Team Leader, Pharmacology/Drug Development,
`2002-2003)
`Translational Research Task Force 2005
`Cancer Research Committee 2007-2010 (Chair, Pre-Phase III Working Group 2008-2010)
`
`European Organization for Research and Treatment of Cancer
`Pharmacology and Molecular Mechanisms Group (Corresponding Member) 1990-2004
`
`National Board of Medical Examiners
`Step 3 Test Material Development Committee for Utilization of Resources, United States Medical
`Licensing Examination 1997-1998
`
`Pharmacogenomics (previously Pharmacogenetics) of Anticancer Agents Research Group
`Founding Chair 2000-2015
`
`Pharmacogenomics (previously Pharmacogenetics) Research Network
`Steering Committee 2000-2015 (Chair, 2000-2003)
`Coordinating Committee 2003-2004, 2007-2008
`Cancer Partnerships Working Group 2006-2010 (Co-Chair, 2006-2010)
`
`U.S. Pharmacopeia
`Oncologic Disease Expert Committee 2000-2003
`
`Institut Pasteur Euroconferences
`Pharmacogenomics 2, Scientific Committee 2001-2002
`
`American Board of Clinical Pharmacology
`Governing Board 2002-2007
`Credentials Committee 2002-2007 (Chair, 2004-2007)
`
`American Association for Cancer Research
`Program Committee 2002-2003, 2006-2007, 2012-2013, 2014-2016
`Scientific Committee AACR-EORTC-NCI Symposia 2003-2006
`Education Committee 2006-2007
`Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant Scientific Review
`Committee 2012-2015
`
`Accreditation Council for Continuing Medical Education
`Content Validation Advisory Group 2003
`
`5
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`Sapporo Cancer Seminar Foundation
`25th International Symposium, Organizing Committee 2005
`
`Japanese Foundation for Cancer Research
`International Symposia, Member 2007-2014
`
`The ASCO Foundation
`Translational Research Professorship Review Subcommittee 2007-2008
`
`Alliance for Clinical Trials in Oncology
`Pharmacogenomics and Population Pharmacology Committee 2011- (Chair, 2011- )
`
`International Workshops on Dose Optimization Strategies for Targeted Drugs
`1st International Workshop on Dose Optimization Strategies for Targeted Drugs: Focus on
`Oncolytics (Zaandam, Netherlands), Co-Chair 2015
`
`6
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`Institutional Committees
`
`Michael Reese Hospital and Medical Center
`Intern Selection Committee, Department of Medicine 1987-1988
`Institutional Review Board, Alternate 1988-1989
`Pharmacy, Therapeutics and Antibiotic Committee 1988-1989
`
`The University of Chicago
`Chairman, Office of Research Services Faculty Advisory Committee, Biological Sciences Division
`1992-1995
`Executive Committee, Cancer Research Center 1992-2004
`Divisional Executive Committee, Biological Sciences Division 1992-2009
`Clinical Chairmen's Committee, Biological Sciences Division 1992-2007
`American Cancer Society Institutional Research Grant Committee, Cancer Research Center
`1994-1998
`Clinical Trials Director Search Committee, Department of Health Studies 1997-1998
`Co-Chair, Pharmacoepidemiology Search Committee 1998-1999
`Chair, Entrepreneurs Committee, Department of Medicine 1999-2000
`Radiology Search Committee, Biological Sciences Division 2000-2001
`Committee on Appointments and Promotions, Biological Sciences Division 2000-2004
`Chair, Clinical Research Working Group, Department of Medicine 2000-2001
`Protocol Accrual Closure and Monitoring Committee, Cancer Research Center 2000-2001
`Committee on Intellectual Property 2001-2004
`Population Sciences Search Committee, Cancer Research Center 2001
`Human Genetics Search Committee, Biological Sciences Division 2002-2003
`t
`2004-
`Cancer Advisory Committee, Comprehensive Cancer Center
`Clinical Research Oversight Committee, Cancer Research Center 2004- (Chair 2004-2007)
`Cardiology Search Committee, Department of Medicine 2005-2006
`Entrepreneurial and Translational Science Advisory Committee, Department of Medicine 2006-
`2007
`Clinical Research Advisory Committee, Comprehensive Cancer Centert 2007- (Chair 2007- )
`Executive Committee, Comprehensive Cancer Centert 2008-
`UChicago Tech Faculty Advisory Committee, 2008-2010
`Chicago Innovation Initiative Working Group, 2012-2013
`Research Strategy Advisory Committee, Department of Medicine 2016-
`
`The University of Chicago Medicine
`Risk Management and Patient Safety Executive Committee, 2013-
`
`7
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`Service to Other Institutions
`
`Georgetown University
`External Scientific Advisory Committee, Lombardi Cancer Center 2002-2011
`
`St. Jude Children’s Research Hospital
`External Advisory Board, Cancer Center 2005-
`
`The First People’s Hospital Affiliated Shanghai Jiangtong University
`External Scientific Advisor in Pharmacogenetics, The Shanghai Transplantation Research Center
`2008
`
`Thomas Jefferson University
`External Scientific Advisory Committee, Kimmel Cancer Center 2009-2013
`
`Radboud University
`Scientific Advisory Board, EuroTARGET 2011-2016
`
`Dartmouth University
`External Scientific Advisory Board, Norris Cotton Cancer Center 2013-
`
`University of Texas Southwestern
`External Advisory Board, Kidney SPORE 2014-
`
`U-PGx Consortium
`Scientific Advisory Board 2016-
`
`National University Cancer Centre Singapore
`Scientific Advisory Board 2016-
`
`Regional Committees
`
`1987-1992
`1987-1992
`1989-1992
`1990-1991
`
`Certification
`
`1981
`1983
`1983
`1985
`1986
`1993
`2014-
`
`New Agents Committee, Illinois Cancer Council
`Biological Response Modifiers Committee, Illinois Cancer Council
`Chemoprevention Committee, Illinois Cancer Council
`Illinois Division Research Committee, American Cancer Society
`
`Diplomate, National Board of Medical Examiners
`Licensed Physician and Surgeon, State of Illinois
`Diplomate, American Board of Internal Medicine
`Diplomate, Medical Oncology, American Board of Internal Medicine
`Diplomate, Hematology, American Board of Internal Medicine
`Diplomate, American Board of Clinical Pharmacology
`Maintenance of Certification, Internal Medicine, Medical Oncology, and
`Hematology, American Board of Internal Medicine
`
`8
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`Professional Membership
`
`1983-
`1986-
`1986-
`1987-
`1988-
`1988-
`1990-
`1992-
`2007-
`2011-
`
`American College of Physicians (Fellow, 1990)
`American Society of Clinical Oncology (Fellow, 2007)
`American Federation for Clinical Research
`American Society for Clinical Pharmacology and Therapeutics
`American Association for Cancer Research
`American Society of Hematology
`Central Society for Clinical Research
`European Society for Medical Oncology
`Association of American Physicians
`American College of Clinical Pharmacology (Honorary Fellow, 2011)
`
`9
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`Honors and Awards
`
`1975
`1985
`1993
`1994-
`1997-
`1999
`1999-
`2001
`2002-
`2002-
`2004
`
`2005-
`2005
`2006
`2007
`2007
`2008
`2008
`
`2009
`2009
`
`2010
`
`2010
`2011
`2011
`2011
`2011
`2012
`
`2012
`
`2013
`2014
`2014
`2014
`2015
`
`2016
`
`Dreyfus Fellowship, Harvard University, Department of Biochemistry
`Central Society for Clinical Research, Trainee Award
`Unit Award, Pharmaceutical Research and Manufacturers of America Foundation
`Listed in The Best Doctors in America (Woodward/White)
`Listed in Chicago’s Top Doctors, Chicago
`Honorary Visiting Expert, Ministry of Health, Singapore
`Listed in America’s Top Doctors (Castle Connolly)
`Distinguished Lecturer, Cancer Institute of New Jersey
`Listed in Top Doctors: Chicago Metro Area (Castle Connolly)
`Leon O. Jacobson Professorship, The University of Chicago
`Top Membership Recruiter, American Society for Clinical Pharmacology and
`Therapeutics
`Listed in America’s Top Doctors for Cancer (Castle Connolly)
`Special Recognition Award, National Cancer Institute
`Chair, 60th Annual Senior Scientific Session, The University of Chicago
`Elected to Association of American Physicians
`Statesman Award, American Society of Clinical Oncology
`Emil J. Freireich Award for Clinical Research, MD Anderson Cancer Center
`Institute for Pharmacogenomics and Individualized Therapy Clinical Service Award, The
`University of North Carolina at Chapel Hill
`Director’s Service Award, National Cancer Institute
`Research Achievement Award in Clinical Pharmacology and Translational Research,
`American Association of Pharmaceutical Scientists
`Rawls-Palmer Progress in Medicine Award, American Society for Clinical Pharmacology
`and Therapeutics
`Henry T. Lynch Lectureship in Medical Genetics, NorthShore University Health System
`Robert Hart Waldman, M.D., Lecture, The University of Nebraska Medical Center
`Translational Research Professorship, American Society of Clinical Oncology
`Certificate of Appreciation, Japanese Society of Medical Oncology
`Honorary Fellow, American College of Clinical Pharmacology
`Visiting Professor, Food and Drug Administration, Center for Drug Evaluation and
`Research, Office of Clinical Pharmacology
`Special Recognition, Department of Pharmaceutics and Pharmaceutical Chemistry,
`College of Pharmacy, University of Utah
`Spotlight on Science Featured Speaker, American Society of Health System Pharmacists
`Keynote Speaker, University of Illinois College of Medicine Research Symposium
`Keynote Speaker, Hospital Pharmacy Europe Live
`Keynote Speaker, Emory University Phase I Unit Five Year Celebration
`Award in Excellence in Clinical Pharmacology, Pharmaceutical Research and
`Manufacturers of America Foundation
`Nominee (Scientific Advances), Giants of Cancer Care, OncLive
`
`10
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`Significant Editorial Responsibilities
`
`1990-2003
`1994-1996
`1995-
`1996-2002
`1999-2001
`1999
`2001-2007
`2001-2004
`2001-2008
`2003-
`2003-2009
`2005-
`2012-
`
`Patents
`
`1998
`
`2002
`
`2002
`
`2004
`
`2008
`
`2010
`
`2014
`
`Cancer Chemotherapy and Pharmacology, Editorial Board
`Clinical Cancer Research, Editorial Board
`Investigational New Drugs, Editorial Advisory Board
`Clinical Cancer Research, Associate Editor
`Clinical Pharmacology and Therapeutics, Editorial Advisory Committee
`Classic Papers and Current Comments: Clinical Pharmacology, Guest Editor
`Journal of Clinical Oncology, Associate Editor
`Current Pharmacogenomics, Editor-in-Chief
`Clinical Pharmacology and Therapeutics, Editorial Board
`Clinical Advances in Hematology & Oncology, Section Editor in Oncology
`Clinical Cancer Research, Editorial Board
`Pharmacogenetics and Genomics, Co-Editor-in-Chief
`Clinical Cancer Research, Editorial Board
`
`Camptothecin drug combinations and methods with reduced side effects (inventors Mark
`J. Ratain & Elora Gupta), United States Patent No.: 5,786,344 (7/28/1998)
`
`Methods for detection of promoter polymorphism in a UGT gene promoter (inventors
`Anna Di Rienzo, Lalitha Iyer & Mark J. Ratain), United States Patent No.: 6,395,481
`(5/28/2002)
`
`Methods for detection of promoter polymorphism in a UGT gene promoter (inventors
`Anna Di Rienzo, Lalitha Iyer & Mark J. Ratain), United States Patent No.: 6,472,157
`(10/29/2002)
`
`Campothecin drug combination and methods with reduced side effects (inventors Mark J.
`Ratain & Elora Gupta), European Patent No.: 0768895 (9/22/2004)
`
`Methods and compositions for predicting irinotecan toxicity (inventors Mark J. Ratain,
`Federico Innocenti, Anna Di Rienzo & Carrie Grimsley), European Patent No.: 1629111
`(5/28/2008)
`
`Methods for predicting irinotecan toxicity (inventors Mark J. Ratain, Federico Innocenti,
`Anna Di Rienzo & Carrie Grimsley), United States Patent No.: 7,807,350 (10/5/2010)
`
`Method for identification of sensitivity of a patient to telomerase inhibition therapy
`(inventors Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio
`Benedetti), United States Patent No.: 8,877,723 (11/4/2014)
`
`Mailing Address:
`
`Mark J. Ratain, M.D.
`The University of Chicago Medicine
`MC2115
`5841 S. Maryland Avenue
`Chicago, Illinois 60637
`Email: mratain@medicine.bsd.uchicago.edu or mjr1@uchicago.edu
`Telephone: (773) 702-4400
`Fax: (773) 702-3969
`
`11
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`Original Research Articles
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`10.
`
`11.
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`17.
`
`Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K. Treatment of hairy cell
`leukemia with recombinant alpha-2-interferon. Blood 65, 644-648 (1985).
`
`Bardawil RG, Groves C, Ratain MJ, Golomb HM, Vardiman JW. Changes in peripheral blood and
`bone marrow specimens following therapy with recombinant alpha2 interferon for hairy cell
`leukemia. Am J Clin Path 85, 194-201 (1986).
`
`Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Vardiman
`J, Burke J, Brady J, Bonnem E, Spiegel R. Alpha-2 interferon therapy of hairy cell leukemia: A
`multicenter study of 64 patients. J Clin Oncol 4, 900-905 (1986).
`
`Schilsky RL, O'Laughlin K, Ratain MJ. Phase I clinical and pharmacological study of thymidine
`(NSC 21548) and cis-diamminedichloroplatinum (II) in patients with advanced cancer. Cancer
`Res 46, 4184-4188 (1986).
`
`Ratain MJ, Vogelzang NJ. Phase I and pharmacological study of vinblastine by prolonged
`continuous infusion. Cancer Res 46, 4827-4830 (1986).
`
`Bennett CL, Vogelzang NJ, Ratain MJ, Reich S. Hyponatremia and other toxic effects during a
`phase I trial of recombinant human gamma interferon and vinblastine. Cancer Treat Rep 70,
`1081-1084 (1986).
`
`Ratain MJ, Vogelzang NJ, Sinkule JA. Interpatient and intrapatient variability in vinblastine
`pharmacokinetics. Clin Pharmacol Ther 41, 61-67 (1987).
`
`Ratain MJ, Golomb HM, Bardawil RG, Vardiman JW, Westbrook CA, Kaminer LS, Lembersky
`BC, Bitter MA, Daly K. Durability of responses to interferon alfa-2b in advanced hairy cell
`leukemia. Blood 69, 872-877 (1987).
`
`Vokes EE, Bitter MA, Ratain MJ, Prystowsky MB, Daly K, Golomb HM. Flow cytometry in hairy
`cell leukemia before and during interferon alfa-2b therapy. Cancer 59, 1987-1991 (1987).
`
`Ratain MJ, Vogelzang NJ. Limited sampling model for vinblastine pharmacokinetics. Cancer
`Treat Rep 71, 935-939 (1987).
`
`Ratain MJ, Kaminer LS, Bitran JD, Larson RA, LeBeau MM, Skosey C, Purl S, Hoffman PC,
`Wade J, Vardiman JW, Daly K, Rowley JD, Golomb HM. Acute nonlymphocytic leukemia
`following etoposide and cisplatin combination chemotherapy for advanced non-small cell
`carcinoma of the lung. Blood 70, 1412-1417 (1987).
`
`Vogelzang NJ, Ruane M, Ratain MJ, Dhowlatshahi K, Chodak GW. A programmable and
`implantable pumping system for systemic chemotherapy: A performance analysis in 52 patients.
`J Clin Oncol 5, 1968-1976 (1987).
`
`Lembersky BC, Ratain MJ, Westbrook C, Golomb HM. Rapid response to 2'deoxycoformycin in
`advanced hairy cell leukemia after failure of interferons alpha and gamma. Amer J Hematol 27,
`60-62 (1988).
`
`Golomb HM, Ratain MJ, Fefer A, Thompson J, Golde DW, Ozer H, Portlock C, Silber R,
`Rappeport J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW. Randomized study of
`the duration of treatment with interferon alfa-2b in patients with hairy cell leukemia. J Natl Cancer
`Inst 80, 369-373 (1988).
`
`Vardiman JW, Gilewski TA, Ratain MJ, Bitter MA, Bradlow BA, Golomb HM. Evaluation of Leu M-
`5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique.
`Am J Clin Path 90, 250-256 (1988).
`
`Lembersky BC, Ratain MJ, Golomb HM. Skeletal complications in hairy cell leukemia: diagnosis
`and therapy. J Clin Oncol 6, 1280-1284 (1988).
`
`Ratain MJ, Staubus AE, Schilsky RL, Malspeis L. Limited sampling models for amonafide (NSC
`308847) pharmacokinetics. Cancer Res 48, 4127-4130 (1988).
`12
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`18.
`
`19.
`
`20.
`
`21.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`28.
`
`29.
`
`30.
`
`31.
`
`32.
`
`33.
`
`34.
`
`Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA, Bitran JD. Human plasma
`pharmacokinetics of thiotepa following administration of high-dose thiotepa and
`cyclophosphamide. J Clin Oncol 6, 1192-1196 (1988).
`
`Ratain MJ, Vardiman JW, Barker CM, Golomb HM. Prognostic variables in hairy cell leukemia
`after splenectomy as initial therapy. Cancer 62, 2420-2424 (1988).
`
`Ratain MJ, Golomb HM, Vardiman JW, Westbrook CA, Barker C, Hooberman A, Bitter MA, Daly
`K. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: Analysis of prognostic
`variables. J Clin Oncol 6, 1714-1721 (1988).
`
`Ratain MJ, Schilsky RL, Wojack BR, Simon T, Senekjian E, Vogelzang NJ. Hydroxyurea and
`etoposide: In vitro synergy and phase I clinical trial. J Natl Cancer Inst 80, 1412-1416 (1988).
`
`Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA. Pharmacokinetics and
`pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther 45, 340-
`347 (1989).
`
`Vokes EE, Schilsky RL, Choi KE, Magid DM, Guarnieri CM, Whaling SM, Ratain MJ,
`Weichselbaum RR, Panje WR. A randomized study of inpatient versus outpatient continuous
`infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer 63, 30-
`36 (1989).
`
`Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E, Liebner
`MA. Adaptive control of etoposide dosing: Impact of interpatient pharmacodynamic variability.
`Clin Pharmacol Ther 45, 226-233 (1989).
`
`Choi KE, Ratain MJ, Williams SF, Golick JA, Beschorner JC, Fullem L, Bitran JD. Plasma
`pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy
`and autologous bone marrow reinfusion. Cancer Res 49, 1318-1321 (1989).
`
`Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA. A limited sampling
`strategy for cyclophosphamide pharmacokinetics. Cancer Res 49, 3129-3133 (1989).
`
`Moormeier J, Ratain MJ, Vardiman JW, Daly K, Golomb HM. Low dose interferon in hairy cell
`leukemia. J Natl Cancer Inst 81, 1172-1174 (1989).
`
`Moormeier J, Westbrook CA, Ratain MJ, Golomb HM. Interferon alfa-2B antibodies and clinical
`resistance in a patient with hairy cell leukemia. Leukemia Lymphoma 1, 43-45 (1989).
`
`Johnston C, Senekjian EK, Ratain MJ, Talerman A. Conservative management of primary
`cervical lymphoma using combination chemotherapy: a case report. Gynecol Oncol 35, 391-394
`(1989).
`
`Schilsky RL, Ratain MJ. Clinical pharmacokinetics of high dose leucovorin after intravenous and
`oral administration. J Natl Cancer Inst 82, 1411-1415 (1990).
`
`Richards JM, Mick R, Latta JM, Daly K, Ratain MJ, Vardiman JW, Golomb HM. Serum soluble IL-
`2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood
`76, 1941-1945 (1990).
`
`Ratain MJ, Robert J, van der Vijgh WJF. Limited sampling models for doxorubicin
`pharmacokinetics. J Clin Oncol 9, 871-876 (1991).
`
`Vokes EE, Ratain MJ, Janisch L, Hoffman PC, Golomb HM, Schilsky RL. A phase I study of
`cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy
`naive patients. Eur J Cancer 27, 217-218 (1991).
`
`Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ,
`Thompson J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW. Survival experience of
`195 patients with hairy cell leukemia treated in a multi-institutional study with interferon-alfa 2b.
`Leukemia Lymphoma 4, 99-102 (1991).
`
`13
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`35.
`
`36.
`
`37.
`
`38.
`
`39.
`
`40.
`
`41.
`
`42.
`
`43.
`
`44.
`
`45.
`
`46.
`
`47.
`
`48.
`
`49.
`
`50.
`
`Vokes EE, Raschko JW, Vogelzang NJ, Warfield EE, Ratain MJ, Doroshow JH, Schilsky RL. Five
`day infusion fluorodeoxyuridine with high dose oral leucovorin: A phase I study. Cancer
`Chemother Pharmacol 28, 69-73 (1991).
`
`Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically-based dosing of
`etoposide: A means of safely increasing dose-intensity. J Clin Oncol 9, 1480-1486 (1991).
`
`Golomb HM, Ratain MJ, Fefer A, Thompson J, Portlock CS, Ozer H, Mick R, Chiavello J, Israel
`RJ, Bonnem EM. Low dose interferon alfa-2B for the induction of remission of hairy cell leukemia:
`A multi-institutional study of 49 patients. Leukemia Lymphoma 5, 335-340 (1991).
`
`Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ, Ratain MJ. Treatment
`of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J
`Clin Oncol 9, 2021-2026 (1991).
`
`Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Paradoxical
`relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 50, 573-
`579 (1991).
`
`Mick R, Ratain MJ. Modeling interpatient pharmacodynamic variability of etoposide. J Natl
`Cancer Inst 83, 1560-1564 (1991).
`
`Vokes EE, Moormeier JA, Ratain MJ, Egorin MJ, Haraf DJ, Mick R, Weichselbaum RR. 5-
`fluorouracil, hydroxyurea, and escalating doses of continuous infusion cisplatin with concomitant
`radiotherapy: A clinical and pharmacologic study. Cancer Chemother Pharmacol 29, 178-184
`(1992).
`
`Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, Jones RJ. A phase I/II
`trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 84, 98-
`103 (1992).
`
`Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M. Ethical issues in phase I oncology
`research: A comparison of investigators and IRB chairpersons. J Clin Oncol 10, 1810-1816
`(1992).
`
`Golomb HM, Ratain MJ, Mick R, Daly K. Interferon treatment for hairy cell leukemia; an update
`on a cohort of 69 patients treated from 1983-86. Leukemia 6,1177-1180 (1992).
`
`Schilsky RL, Ratain MJ, Janisch L, Vogelzang NJ, Lucas VS, Ravitch J, Hohneker JA,
`Clendeninn NJ, Tuttle RL. Phase I clinical and pharmacologic study of 502U83 administered as a
`24 hour continuous intravenous infusion. Cancer Chemother Pharmacol 31, 283-288 (1993).
`
`Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Hamasaki V, Kozloff M, Weichselbaum RR,
`Panje WR, Wenig B, Berezin F. Cisplatin, 5-fluorouracil and leucovorin augmented by interferon
`alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 11, 360-368
`(1993).
`
`Mick R, Ratain MJ. Model-guided determination of maximal tolerated dose in phase I clinical
`trials: Evidence for increased precision. J Natl Cancer Inst 85, 217-223 (1993).
`
`Ratain MJ, Priest E, Janisch L, Vogelzang NJ. Phase I study of subcutaneous recombinant
`interleukin-2 and interferon alfa-2a. Cancer 71, 2371-2376 (1993).
`
`Schilsky RL, Janisch L, Berezin F, Mick R, Vogelzang NJ, Ratain MJ. Phase I clinical and
`pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
`Cancer Res 53, 1293-1296 (1993).
`
`Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Phase I study of
`amonafide dosing based on acetylator phenotype. Cancer Res 53, 2304-2308 (1993).
`
`14
`
`

`
`Ratain Curriculum Vitae – Revised 12/19/2016
`
`51.
`
`52.
`
`53.
`
`54.
`
`55.
`
`56.
`
`57.
`
`58.
`
`59.
`
`60.
`
`61.
`
`62.
`
`63.
`
`64.
`
`65.
`
`66.
`
`Vokes EE, Dolan ME, Krishnasamy S, Mick R, Ratain MJ, Berezin F, Brachman D, Whitman G,
`Schilsky RL, Weichselbaum RR, Charette J, Dohrmann GJ, Hekmatpanah J. 5-fluorouracil,
`hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for
`malignant gliomas: a clinical and pharmacologic analysis. Ann Oncol 4, 591-595 (1993).
`
`Vokes EE, O'Brien S, Vogelzang NJ, Schilsky RL, Ratain MJ. Five day infusional
`fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alfa-2b: a phase I study.
`Cancer Chemother Pharmacol 32, 347-352 (1993).
`
`Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Norton L, Vogelzang
`NJ, Schilsky RL. Phase I trial of granulocyte-macrophage colony stimulating factor plus high-dose
`cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer
`Inst 85, 1319-1326 (1993).
`
`Samuels BL, Mick R, Vogelzang NJ, Williams SF, Schilsky RL, Safa AR, O'Brien S, Ratain MJ.
`Modulation of vinblastine resistance with cyclosporine A: a phase I study. Clin Pharmacol Ther
`54, 421-429 (1993).
`
`Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ. A phase I and
`pharmacokinetic study of a new an